NZ503174A - A synergistic combination of a benzopyran selective 5-HT 1A antagonist and a selective h5-HT 1B antagonist or partial agonist - Google Patents

A synergistic combination of a benzopyran selective 5-HT 1A antagonist and a selective h5-HT 1B antagonist or partial agonist

Info

Publication number
NZ503174A
NZ503174A NZ503174A NZ50317498A NZ503174A NZ 503174 A NZ503174 A NZ 503174A NZ 503174 A NZ503174 A NZ 503174A NZ 50317498 A NZ50317498 A NZ 50317498A NZ 503174 A NZ503174 A NZ 503174A
Authority
NZ
New Zealand
Prior art keywords
benzopyran
dihydro
tetrahydro
methylpiperazin
compound
Prior art date
Application number
NZ503174A
Other languages
English (en)
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NZ503174A publication Critical patent/NZ503174A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ503174A 1997-09-18 1998-09-09 A synergistic combination of a benzopyran selective 5-HT 1A antagonist and a selective h5-HT 1B antagonist or partial agonist NZ503174A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703374A SE9703374D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001600 WO1999013876A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (1)

Publication Number Publication Date
NZ503174A true NZ503174A (en) 2002-03-01

Family

ID=20408294

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ503174A NZ503174A (en) 1997-09-18 1998-09-09 A synergistic combination of a benzopyran selective 5-HT 1A antagonist and a selective h5-HT 1B antagonist or partial agonist

Country Status (29)

Country Link
US (1) US6159972A (cg-RX-API-DMAC10.html)
EP (1) EP1021183B1 (cg-RX-API-DMAC10.html)
JP (1) JP2001516717A (cg-RX-API-DMAC10.html)
KR (1) KR20010024075A (cg-RX-API-DMAC10.html)
CN (1) CN1182847C (cg-RX-API-DMAC10.html)
AR (1) AR015447A1 (cg-RX-API-DMAC10.html)
AT (1) ATE261728T1 (cg-RX-API-DMAC10.html)
AU (1) AU752718B2 (cg-RX-API-DMAC10.html)
BR (1) BR9812234A (cg-RX-API-DMAC10.html)
CA (1) CA2302383A1 (cg-RX-API-DMAC10.html)
DE (1) DE69822490T2 (cg-RX-API-DMAC10.html)
DK (1) DK1021183T3 (cg-RX-API-DMAC10.html)
EE (1) EE04142B1 (cg-RX-API-DMAC10.html)
ES (1) ES2216307T3 (cg-RX-API-DMAC10.html)
HU (1) HUP0100401A3 (cg-RX-API-DMAC10.html)
IL (1) IL134774A0 (cg-RX-API-DMAC10.html)
IS (1) IS5408A (cg-RX-API-DMAC10.html)
MY (1) MY116281A (cg-RX-API-DMAC10.html)
NO (1) NO20001398L (cg-RX-API-DMAC10.html)
NZ (1) NZ503174A (cg-RX-API-DMAC10.html)
PL (1) PL339370A1 (cg-RX-API-DMAC10.html)
PT (1) PT1021183E (cg-RX-API-DMAC10.html)
RU (1) RU2215528C2 (cg-RX-API-DMAC10.html)
SE (1) SE9703374D0 (cg-RX-API-DMAC10.html)
SK (1) SK2842000A3 (cg-RX-API-DMAC10.html)
TR (1) TR200000734T2 (cg-RX-API-DMAC10.html)
TW (1) TW568786B (cg-RX-API-DMAC10.html)
WO (1) WO1999013876A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA987810B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
USD969018S1 (en) 2021-06-28 2022-11-08 Koninklijke Asscher Diamant Maatschappij B.V. Rose pear diamond article

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA90673B (en) * 1989-02-02 1990-10-31 Yamanouchi Pharma Co Ltd Tetrahydrobenzimidazole derivatives
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9410512D0 (en) * 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
FI961247A0 (fi) * 1996-03-18 1996-03-18 Finnish Peroxides Ab Oy Foerfarande foer loesning av uppsvaellningsproblem i en avfalls vattenreningsanordning foer kontroll av traodartiga bakterier
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
SK2842000A3 (en) 2000-09-12
AR015447A1 (es) 2001-05-02
AU752718B2 (en) 2002-09-26
EP1021183B1 (en) 2004-03-17
IL134774A0 (en) 2001-04-30
TR200000734T2 (tr) 2000-11-21
MY116281A (en) 2003-12-31
NO20001398D0 (no) 2000-03-17
ZA987810B (en) 1999-02-18
PT1021183E (pt) 2004-07-30
CA2302383A1 (en) 1999-03-25
DK1021183T3 (da) 2004-07-05
CN1182847C (zh) 2005-01-05
RU2215528C2 (ru) 2003-11-10
WO1999013876A1 (en) 1999-03-25
DE69822490T2 (de) 2005-03-03
CN1279609A (zh) 2001-01-10
TW568786B (en) 2004-01-01
US6159972A (en) 2000-12-12
SE9703374D0 (sv) 1997-09-18
HUP0100401A2 (hu) 2002-01-28
ES2216307T3 (es) 2004-10-16
NO20001398L (no) 2000-04-04
HK1032740A1 (en) 2001-08-03
PL339370A1 (en) 2000-12-18
AU9192998A (en) 1999-04-05
BR9812234A (pt) 2000-07-18
DE69822490D1 (de) 2004-04-22
IS5408A (is) 2000-03-15
EE04142B1 (et) 2003-10-15
JP2001516717A (ja) 2001-10-02
HUP0100401A3 (en) 2003-01-28
ATE261728T1 (de) 2004-04-15
EE200000143A (et) 2001-02-15
KR20010024075A (ko) 2001-03-26
EP1021183A1 (en) 2000-07-26

Similar Documents

Publication Publication Date Title
AU752722B2 (en) A combination of a 5-HT reuptake inhibitor and a h5-HT 1B antagonist or partial agonist
US6410532B2 (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
EP1014986B1 (en) A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT 1 BETA ANTAGONIST OR PARTIAL AGONIST
EP1025095B1 (en) Substituted chroman derivatives
AU752718B2 (en) A combination of a selective 5-HT1A antagonist and a selective h5-HT1B antagonist or partial agonist
HK1032740B (en) A combination of a selective 5-ht1a antagonist and a selective h5-ht1b antagonist or partial agonist
HK1032739B (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
MXPA00002623A (en) A combination of a selective 5-ht1a
MXPA00002612A (en) A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B
MXPA00000676A (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
CZ2000944A3 (cs) Kombinace inhibitoru monoaminoxidázy a antagonisty nebo parciárního agonisty Ii5-HT1B

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)